SAB BIOTHERAPEUTICS, INC. Operating Lease Cost
SAB BIOTHERAPEUTICS, INC. (SABS) reported Operating Lease Cost of $246.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-06-30 was $246.00K, a 8.21% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-06-30 was $268.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month |
|---|---|---|
| 2026-06-30 | $246.00K 10-Q · filed 2026-08-06 | $547.00K 10-Q · filed 2026-08-06 |
| 2025-06-30 | $268.00K 10-Q · filed 2026-08-06 | $536.00K 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |